Although methods in diagnosis and therapy of hepatocellular carcinoma (HCC) have made significant progress in decades, the overall survival (OS) of HCC remains dissatisfactory, so it is particularly important to find better diagnostic and prognostic biomarkers. In this study, we found a more reliable potential diagnostic biomarkers and constructed a more accurate prognostic evaluation model based on integrated transcriptome sequencing analysis of multiple independent data sets. First, we performed quality evaluation and differential analysis on seven Gene Expression Omnibus (GEO) data sets, and then comprehensively analyzed the differentially expressed genes with a robust rank aggregation algorithm. Next, Least absolute shrinkage and selection operator (LASSO) regression was used to establish an 8-gene prognostic risk score (RS) model. Finally, the prognostic model was further validated in the GEO data set. Also, RS has independence on other clinicopathological characteristics but has similarities in prognostic assessment compared with the T stage. Moreover, the combination of T stage and prognostic RS model based on the 8-gene had a better prognostic evaluation effect. In brief, our research suggest that the prognostic risk model of 8 genes has important clinical significance in HCC patients, and can further enrich the prognostic guidance value of the traditional T stage.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jcb.29480 | DOI Listing |
Discov Oncol
January 2025
Department of Laboratory, Ningbo Yinzhou No.2 Hospital, No.998 Qianhe Road, Yinzhou Distrinct, Ningbo, 315100, China.
Background: Clear cell renal cell carcinoma (ccRCC) remains a challenging cancer type due to its resistance to standard treatments. Immunogenic cell death (ICD) has the potential to activate anti-tumor immunity, presenting a promising avenue for ccRCC therapies.
Methods: We analyzed data from GSE29609, TCGA-KIRC, and GSE159115 to identify ICD-related prognostic genes in ccRCC.
Eur Radiol
January 2025
Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Objectives: We aimed to use artificial intelligence to accurately identify molecular subgroups of medulloblastoma (MB), predict clinical outcomes, and incorporate deep learning-based imaging features into the risk stratification.
Methods: The MRI features were extracted for molecular subgroups by a novel multi-parameter convolutional neural network (CNN) called Bi-ResNet-MB. Then, MR features were used to establish a prognosis model based on XGBoost.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, West China Hospital, Sichuan University, No.37, Guoxue Alley, Chengdu City, Sichuan Province, 610041, China.
Background: Pathological grade is a critical determinant of clinical outcomes and decision-making of follicular lymphoma (FL). This study aimed to develop a deep learning model as a digital biopsy for the non-invasive identification of FL grade.
Methods: This study retrospectively included 513 FL patients from five independent hospital centers, randomly divided into training, internal validation, and external validation cohorts.
Endovascular thrombectomy (EVT) dramatically improves clinical outcomes, but the final infarct volume (FIV) on MRI only accounts for a minority of the treatment effect. An imaging biomarker that more strongly correlates with post-EVT functional outcome would be helpful for clinical prognosis and serve as a surrogate outcome measure in trials of EVT-adjuvant therapies. Here, we aimed to validate a novel MRI-based metric, infarct density, which leverages post-EVT apparent diffusion coefficient (ADC) as a marker of infarct severity.
View Article and Find Full Text PDFFront Oncol
January 2025
Angiogenesis Group, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain.
[This corrects the article DOI: 10.3389/fonc.2024.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!